{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T08:28:45Z","timestamp":1648542525952},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T00:00:00Z","timestamp":1406764800000},"content-version":"vor","delay-in-days":152,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.5581\/1516-8484.20140020","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T20:51:56Z","timestamp":1395780716000},"page":"96-97","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u201cOutcomes of autologous transplantation for multiple myeloma according to different induction regimens\u201d**See paper by Crusoe EQ et al, on Rev Bras Hematol Hemoter. 2014;36(1):19-24."],"prefix":"10.1016","volume":"36","author":[{"given":"Javier","family":"de la Rubia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.5581\/1516-8484.20140020_bb0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol."},{"issue":"13","key":"10.5581\/1516-8484.20140020_bb0010","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.5581\/1516-8484.20140020_bb0015","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/annonc\/mdm178","article-title":"VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group","volume":"18","author":"Zervas","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.5581\/1516-8484.20140020_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.5581\/1516-8484.20140020_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.5581\/1516-8484.20140020_bb0030","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoieticcell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.5581\/1516-8484.20140020_bb0035","first-page":"108","article-title":"Dexamethasone+thalidomide (Dex\/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial","author":"Macro","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.5581\/1516-8484.20140020_bb0040","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.5581\/1516-8484.20140020_bb0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/ajh.21038","article-title":"Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to highdose melphalan with autologous stem cell support","volume":"82","author":"Vogl","year":"2007","journal-title":"Am J Hematol"},{"issue":"1","key":"10.5581\/1516-8484.20140020_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5581\/1516-8484.20140008","article-title":"Outcomes of autologous transplantation for multiple myeloma according to different induction regimens","volume":"36","author":"Crusoe","year":"2014","journal-title":"Rev Bras Hematol Hemoter"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848414500278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848414500278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T17:23:59Z","timestamp":1538760239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848414500278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1516848414500278"],"URL":"https:\/\/doi.org\/10.5581\/1516-8484.20140020","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}